Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Diabetes; obesity

Adiponectin (ADIPOQ); adiponectin receptor 1 (ADIPOR1); ADIPOR2

Mouse studies suggest a dual ADIPOR1 and ADIPOR2 agonist could help treat obesity and type 2 diabetes. In vitro screening of a small molecule library identified an agonist of ADIPOR1 and ADIPOR2 that bound the receptors with low micromolar affinities. In mouse models of obesity and diabetes, the compound decreased plasma levels of triglycerides and glucose, decreased insulin resistance and increased glucose tolerance compared with vehicle, without affecting weight or food intake. In obese and diabetic mice fed a high-fat diet, the compound increased lifespan compared with no treatment. Planned work includes optimizing and testing the compound in the obesity and diabetes models.

SciBX 6(46); doi:10.1038/scibx.2013.1320
Published online Dec. 5, 2013

Patented by The University of Tokyo; licensing status undisclosed

Okada-Iwabu, M. et al. Nature; published online Oct. 30, 2013;
doi:10.1038/nature12656
Contact: Toshimasa Yamauchi, The University of Tokyo, Tokyo, Japan
e-mail:

tyamau-tky@umin.net